Clinical Study Results
Clinical Study Results
Study Name
Title of the study: An Open-label, Single-dose Study to Evaluate the Safety,
Tolerability, Pharmacokinetics, and Pharmacodynamics of
Etelcalcetide (AMG 416) in Paediatric Subjects Aged 2 to less
than 18 Years with Secondary Hyperparathyroidism (HPT)
Receiving Maintenance Haemodialysis
Brief Title: A Single-dose Study in Paediatric Patients Aged 2 to Less Than
18 Years with Secondary Hyperparathyroidism (sHPT)
Receiving Haemodialysis
Protocol Number: 20140336
EU Trial Number 2015-005051-28
Other Identifiers NCT02833857
Date of This 03 December 2019
Summary devorppA
What does this summary cover?
This summary shows the main results from one clinical study. The results are only for
this study. Other studies may find different results. Researchers and health authorities
look at the results of many studies to decide which medicines work best and are safest
for patients.
1. Who Sponsored This Study?
Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799 USA
Phone (United States): +1 805-447-1000
Amgen Inc. is the sponsor of the study who manufactured etelcalcetide, the
investigational medicine included in the study. Amgen would like to thank everyone who
participated in this study and feels it is important to share the results of this study.
1